We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App




New Test Diagnoses C. difficile with One Assay and No Retesting

By LabMedica International staff writers
Posted on 23 Feb 2015
Print article
The Genspeed C.diff OneStep – a rapid new molecular test that accurately diagnoses toxigenic Clostridium difficile in a single assay
The Genspeed C.diff OneStep – a rapid new molecular test that accurately diagnoses toxigenic Clostridium difficile in a single assay (Photo courtesy of Greiner Bio-One)
A new CE-IVD certified molecular test provides rapid, accurate, single-test detection of toxigenic Clostridium difficile without the need for confirmatory retesting.

Greiner Bio-One International GmbH (Frickenhause, Germany, and Kremsmünster, Austria) has now added the Genspeed C.diff OneStep assay to its growing portfolio of CE-IVD certified molecular diagnostic tests for nosocomial infections. Genspeed C.diff OneStep identifies toxigenic C. difficile by combining detection of 4 biomarkers: glutamatdehydrogenase (GDH), Toxin A, Toxin B, binary toxin in a single test. Complete analysis takes under 100 min (depending on PCR-cycler used), including detection on the Genspeed R2 Analyzer.

Genspeed C.diff OneStep’s new “1-test – 4-results” procedure avoids the currently used sequential 2-step procedures that combine different test systems and assay principles for GDH and the C. difficile toxins. It also provides conclusive results without the need for confirmatory re-testing and enables inter-laboratory comparisons of results.

Ready-to-use reagents and automated dispensing minimize the number of manual processing steps within the workflow. The Genspeed R2 Analyzer represents a reliable solution that is virtually service-free system, simple to operate, and available at an attractive cost-benefit ratio.

The new test addresses one of the most serious threats worldwide as C. difficile causes one of the most common serious healthcare system associated infections. In a 2013 report, the USA Center for Disease Control (CDC) categorized C. difficile infections as “Threat Level Urgent,” the highest level available.

All Genspeed products are currently available for sale in the EU and EFTA countries only.

Related Links:

Greiner Bio-One 
Genspeed Analyzer and Assays
Genspeed C.diff OneStep, assay brochure

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.